UNSPSC 51422117: Fluocortolone acetate

This classification denotes a therapeutic glucocorticoid C24H31FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F0KV2P7H3C, chemically known as pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6-fluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-, but more generally known as fluocortolone acetate, which bears US NIH Compound Identifier 22798516. European Medicines Agency schedules Fluocortolone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02217MIG.

Most nations, for tariff and trade purposes, schedule fluocortolone acetate under HS 29372200 and SITC 54153. As of Q4 2014, FLUOCORTOLONE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@H]1C(=O)COC(=O)C)C)O)C)F.

UNSPSC 51422117 Fluocortolone acetate is a Commodity code that, based on available recent state and local procurement activity, shows minimal substantive match to what is actually being solicited. The single recent opportunity tagged to this code — Seminole County, Florida's IFB for naloxone and safe drug deactivation systems — involves emergency medical and harm-reduction products, not the corticosteroid pharmaceutical that the code nominates. State and local health departments, counties, and emergency services may use this code nominally to classify pharmaceutical procurements, but the gap between the code's specified drug and the actual scope of recent solicitations suggests either miscoding in source systems or a code applied as a catch-all for injectable or topical pharmaceuticals. Issuing bodies using this code appear to include county health departments and county procurement offices.

The geographic footprint based on recent activity is limited to Florida, with Seminole County representing the sole documented recent opportunity. Seminole County's IFB 60459723LAS, posted June 30, 2026, and closing July 26, 2023 (note: the posted and close dates appear inconsistent in the source), sought 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year term with optional one-year renewal, with quarterly deliveries to the Seminole County Community Health Building in Sanford. Bidders were required to submit through the county's e-Procurement Portal, include all shipping and delivery costs, and comply with E-Verify and drug-free workplace certifications. The procurement carried potential FEMA funding and associated federal compliance requirements. No explicit set-aside designations were noted. Given the single recent opportunity and the mismatch between code nomenclature and actual procurement scope, activity under this code does not currently support a strong pursuit signal for firms focused on the specified pharmaceutical.